BTIG Research has recently reduced Ginkgo Bioworks Holdings Inc (DNA) stock to Sell rating, as announced on May 15, 2024, according to Finviz. Earlier, on May 10, 2024, William Blair had reduced the stock from a Mkt Perform to Underperform. Raymond James also reduced Mkt Perform rating with a price target of $2.50. Additionally, BTIG Research reduced Neutral rating on November 9, 2023. Goldman analysts, in their report published on June 2, 2023, also reduced Sell rating and set a price target of $1.25 for Ginkgo Bioworks Holdings Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Ginkgo Bioworks Holdings Inc (DNA) Stock Trading Recap
On Friday, Ginkgo Bioworks Holdings Inc (DNA) stock saw a decline, ending the day at $5.65 which represents a decrease of $-0.49 or -7.98% from the prior close of $6.14. The stock opened at $6.06 and touched a low of $5.64 during the day, reaching a high of $6.15. The volume of shares traded was 1.95 million exceeding the average volume of 1.54 million.
DNA Stock Performance and Moving Averages
In recent trading, Ginkgo Bioworks Holdings Inc (DNA) stock price has shown some volatility, fluctuating -20.31% over the last five trades and -48.52% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -88.23%, and it has plunged by -74.32% in the previous three months. Currently, DNA is trading at -33.63%, -49.40%, and -84.55% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, DNA, a Healthcare sector stock, is trading -93.75% below its 52-week high but remains -5.83% above its 52-week low. The Average True Range (ATR) (14 days) of 1.09 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Ginkgo Bioworks Holdings Inc’s Profitability and Valuation Ratios
Ginkgo Bioworks Holdings Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -348.09% and a profit margin of -486.98%, with a gross margin of -88.23%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Ginkgo Bioworks Holdings Inc’s market capitalization stands at $297.08 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 1.61, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 0.33, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 32.54% of Ginkgo Bioworks Holdings Inc (DNA)’s shares, while financial institutions hold 44.82%.
Notable insider trades include DEKKERS MARIJN E, Director at Ginkgo Bioworks Holdings Inc (DNA), who sold 265000 shares on May 16 ’24, at $0.83 each, totaling $0.22 million. On May 14 ’24, DEKKERS MARIJN E, Director, sold 1727056 shares for $0.93 each, amounting to $1.61 million. Additionally, on May 02 ’24, Coen Steven P. sold 131928 shares at $0.84 each, generating $0.11 million.
